Zobrazeno 1 - 10
of 585
pro vyhledávání: '"levodopa/carbidopa intestinal gel"'
Autor:
Naia Ayo Mentxakatorre, Beatriz Tijero, María Ángeles Acera, Tamara Fernández-Valle, Marta Ruiz-Lopez, Juan Carlos Gómez-Esteban, Rocio Del Pino
Publikováno v:
Frontiers in Nutrition, Vol 11 (2024)
Parkinson’s disease (PD) is characterized by motor and non-motor symptoms. Nutritional alterations are one of the non-motor symptoms that most influence the quality of life (QoL) in PD.ObjectiveTherefore, this review aims to evaluate whether nutrit
Externí odkaz:
https://doaj.org/article/1bf93bfcdae1492f9c40198d2b030c35
Autor:
Eric Freire-Alvarez, Paola Vanni, Egon Kurča, Lydia Lopez-Manzanares, Norbert Kovács, Cleanthe Spanaki, Tianming Gao, Lars Bergmann, Olga Sánchez-Soliño
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 437-447 (2024)
Abstract Introduction The DYSCOVER study was a phase 3b, open-label, randomized trial (NCT02799381) that evaluated levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) in patients with Parkinson’s disease (PD) and a hig
Externí odkaz:
https://doaj.org/article/f7d247ce54b845319554bfe6bbec30d3
Autor:
Masatoshi Nakagawa, Noboru Inoue, Shuhei Takise, Masashi Takayanagi, Tsukasa Kubo, Hiroto Muroi, Masanobu Nakajima, Shinji Morita, Takatoshi Nakamura, Kazuyuki Kojima
Publikováno v:
Surgical Case Reports, Vol 9, Iss 1, Pp 1-5 (2023)
Abstract Background Levodopa–carbidopa intestinal gel (LCIG) treatment is an effective Parkinson’s disease (PD) treatment that requires percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG-J). Buried bumper syndrome (BBS) is an
Externí odkaz:
https://doaj.org/article/7cf7ad3976fd4350a2221c4098537eff
Autor:
Kensuke Ikenaka, Yuta Kajiyama, César Aguirre, Chi‐Jing Choong, Seira Taniguchi, Junko Doi, Nan Wang, Takahiro Ajiki, Kotaro Ogawa, Keita Kakuda, Yasuyoshi Kimura, Hideki Mochizuki
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 1, Pp n/a-n/a (2024)
Abstract The study aims to investigate the vitamin B6 levels in Parkinson's disease (PD) patients and their association with liver enzymes and evaluate how much dysregulation is associated with levodopa dose. Furthermore, to evaluate the effect of Op
Externí odkaz:
https://doaj.org/article/a03a1a17c64044a8b720d28a1db1b6a5
Autor:
Silvia Rota, Daniele Urso, Daniel J. van Wamelen, Valentina Leta, Iro Boura, Per Odin, Alberto J. Espay, Peter Jenner, K. Ray Chaudhuri
Publikováno v:
Translational Neurodegeneration, Vol 11, Iss 1, Pp 1-14 (2022)
Abstract Continuous drug delivery (CDD) is used in moderately advanced and late-stage Parkinson’s disease (PD) to control motor and non-motor fluctuations (‘OFF’ periods). Transdermal rotigotine is indicated for early fluctuations, while subcut
Externí odkaz:
https://doaj.org/article/26cf9af741ac4f178127aa79fb31f5c4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kanefumi Yamashita, Yukinori Yube, Yukinao Yamazaki, Takehide Fukuchi, Masaki Kato, Tomoyuki Koike, Takeshi Uehara, Yoshiou Ikeda, Satoshi Furune, Hidehiro Murakami, Eiji Kubota, Shinsuke Fujioka, Yoshinori Sato, Xiaoyi Jin, Tomohiko Suzuki, Kazuhiro Furukawa, Yoshio Tsuboi
Publikováno v:
BMC Neurology, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Levodopa–carbidopa intestinal gel (LCIG) treatment, a unique drug delivery system for patients with advanced Parkinson’s disease (PD), is covered by health insurance in Japan since September 2016. Various LCIG procedure/device
Externí odkaz:
https://doaj.org/article/3063790ee23e461ebcfbe86d06524d0d
Autor:
Germaine Hiu-Fai Chan
Publikováno v:
Frontiers in Aging Neuroscience, Vol 14 (2022)
Parkinson’s disease (PD) is a common neurodegenerative disease. At present, 5–10% of PD patients are found to have monogenic form of the disease. Each genetic mutation has its own unique clinical features and disease trajectory. It is unclear if
Externí odkaz:
https://doaj.org/article/a96842108c4240c0a079216cf3680e82
Autor:
Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Samuel Muller, Jean Y. H. Yang, Ryan L. Davis, Carolyn M. Sue
Publikováno v:
Frontiers in Aging Neuroscience, Vol 14 (2022)
BackgroundAltered gut microbiome (GM) composition has been established in Parkinson’s disease (PD). However, few studies have longitudinally investigated the GM in PD, or the impact of device-assisted therapies.ObjectivesTo investigate the temporal
Externí odkaz:
https://doaj.org/article/8521f0bebdc34906889e196bcd64bc47